One-fifth of all newly diagnosed breast cancer cases are ductal carcinoma in situ (DCIS), but little is known about DCIS risk factors. Recent studies suggest that some subtypes of DCIS (high grade or comedo) share histopathologic and epidemiologic characteristics with invasive disease, whereas others (medium or low grade or non-comedo) show different patterns. To investigate whether reproductiv...

the focus of this study was to determine if early detection of mutant p53 accumulation may be an early indicator of tumor aggressiveness and transformation to invasive breast cancer. for this purpose, the p53 content of 100 human breast biopsies classified as ductal carcinoma (dcis), was evaluated by immunohistochemical method. all specimens were microscopically classified into histologic types...

PURPOSE To assess the prevalence of phosphoinositide 3-kinase (PI3K) pathway alterations in pure high-grade ductal carcinoma in situ (DCIS) and DCIS associated with invasive breast cancer (IBC), and to determine whether DCIS and adjacent IBCs harbor distinct PI3K pathway aberrations. EXPERIMENTAL DESIGN Eighty-nine cases of pure high-grade DCIS and 119 cases of high-grade DCIS associated with...

Ductal carcinoma in situ (DCIS) is a category of early stage, non-invasive breast tumor defined by the intraductal proliferation of malignant breast epithelial cells. DCIS is a heterogeneous disease composed of multiple molecular subtypes including luminal, HER2 and basal-like types, which are characterized by immunohistochemical analyses and gene expression profiling. Following surgical and ra...

PURPOSE Ductal carcinoma in situ (DCIS) is thought to be a nonobligate precursor of invasive cancer. Genomic changes specific to pure DCIS versus invasive cancer, as well as alterations unique to individual DCIS subtypes, have not been fully defined. EXPERIMENTAL DESIGN Chromosomal copy number alterations were examined by comparative genomic hybridization in 34 cases of pure DCIS and compared...

Background: The nuclear grading of ductal carcinoma in situ (DCIS) affects its clinical risk. aim this study was to investigate the possibility predicting DCIS, by magnetic resonance imaging (MRI)-based radiomics features. And develop a nomogram combining features and MRI semantic explore potential role radiomic assessment DCIS grading.

Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %. Could there be a role for systemic therapy in case of a DCIS? Recent published studies suggest t...

BACKGROUND Clinical and histopathologic characteristics that may predict risks of recurrence in women with ductal carcinoma in situ (DCIS) have not been consistently identified. We identified factors associated with recurrence as DCIS versus invasive breast cancer and determined the 5-year absolute risks of recurrence as a function of these factors. METHODS We conducted a population-based coh...

Purpose: To assess the prevalence of phosphoinositide 3-kinase (PI3K) pathway alterations in pure highgrade ductal carcinoma in situ (DCIS) and DCIS associated with invasive breast cancer (IBC), and to determine whether DCIS and adjacent IBCs harbor distinct PI3K pathway aberrations. Experimental Design: Eighty-nine cases of pure high-grade DCIS and 119 cases of high-grade DCIS associated with ...

Invasive breast cancer (IBC) is a heterogeneous disease which can be divided in several molecular subtypes [1] with distinct biological behavior and clinical outcome. Although these subtypes are based on microarray-based gene expression studies, each molecular subtype has an immunohistochemical surrogate: luminal A (ER+ and PR+/ Her2-, low Ki-67 index), luminal B (ER+, Her2-, PRor low and/or hi...